Background
Methods
Sample collection
The cancer genome atlas (TCGA) colorectal cancer data sets
Isolation of genomic DNA and RNA
Whole-exome sequencing
Exome-seq data analysis
RNA sequencing
RNA-seq data analysis
Organoid culture
Cell transfection
Cell proliferation assay
Real-time quantitative polymerase chain reaction (RT-qPCR) analysis
Cell lysis and Western blot analysis
High-throughput screening (HTS)
Statistical analysis
Results
CMS classification according to age of CRC patients
Young CRC | Middle CRC | Old CRC | |
---|---|---|---|
Number | 13 | 23 | 13 |
Age | < = 40 | 41 – 60 | > 60 |
Sex | |||
Male | 5 (38.5%) | 8 (34.8%) | 10 (76.9%) |
Female | 8 (61.5%) | 15 (65.2%) | 3 (23.1%) |
Tumor location | |||
Colon | 9 (69.2%) | 19 (82.6%) | 12 (92.3%) |
Rectum | 4 (30.8%) | 4 (17.4%) | 1 (7.7%) |
Cell differentiation | |||
Adenocarcinoma | |||
W/D | 2 (15.4%) | 1 (4.3%) | 3 (23.1%) |
M/D | 10 (76.9%) | 18 (78.4%) | 9 (69.2%) |
P/D | 0 (0%) | 3 (13.0%) | 0 (0%) |
Mucinous carcinoma | 1 (7.7%) | 1 (4.3%) | 1 (7.7%) |
Stage | |||
II | 2 (15.4%) | 6 (26.1%) | 1 (7.7%) |
III | 4 (30.8%) | 2 (8.7%) | 3 (23.1%) |
IV | 7 (53.8%) | 15 (65.2%) | 9 (69.2%) |
MSI status | |||
MSS | 13 (100%) | 20 (87%) | 13 (100%) |
MSI | 0 (0%) | 3 (13%) | 0 (0%) |
Differential mRNA expression and gene profiling between young and old CRC
Gene | Fold change | q-value | Cancer associated | Full Name |
---|---|---|---|---|
WNT11 | 4.33 | 0.012 | Suppressor gene | Wnt family member 11 |
HSPB7 | 3.28 | 0.023 | Suppressor gene | Heat shock protein family B (small) member 7 |
FBLN1 | 3.14 | 0.001 | Suppressor gene | Fibulin 1 |
CNN1 | 2.94 | 0.037 | Suppressor gene | Calponin 1 |
CENPW | 2.34 | 0.021 | Oncogene | Centromere protein W |
LCK | 2.3 | 0.032 | Oncogene | LCK proto-oncogene, Src family tyrosine kinase |
CLU | 2.24 | 0.01 | Suppressor gene | Clusterin |
AQP1 | 2.23 | 0.033 | Oncogene | Aquaporin 1 |
S100A4 | 2.22 | 0.019 | Oncogene | S100 calcium binding protein A4 |
TAGLN | 2.22 | 0.031 | Suppressor gene | Transgelin |
GREM1 | 2.18 | 0.01 | Oncogene | Gremlin 1, DAN family BMP antagonist |
PDGFRA | 2.18 | 0.001 | Oncogene | Platelet derived growth factor receptor alpha |
MMP12 | 2.18 | 0.028 | Oncogene | Matrix metallopeptidase 12 |
SMO | 2 | 0.028 | Oncogene | Smoothened, frizzled class receptor |
Gene | Fold change | q-value | Cancer associated | Full name |
---|---|---|---|---|
ZIC2 | 0.23 | 0.006 | Oncogene | Zic family member 2 |
PPP1R1B | 0.4 | 0.009 | Suppressor gene | Protein phosphatase 1 regulatory inhibitor subunit 1B |
NDRG2 | 0.43 | 0.001 | Suppressor gene | NDRG family member 2 [Homo sapiens |
FEZF1 | 0.44 | 0.039 | Oncogene | FEZ family zinc finger 1 [Homo sapiens |
NFIB | 0.48 | 0.001 | Oncogene | Nuclear factor I B |
ZNF292 | 0.48 | 0.001 | Suppressor gene | Zinc finger protein 292 |
PHLDA2 | 0.48 | 0.001 | Suppressor gene | Pleckstrin homology like domain family A member 2 |
CEACAM6 | 0.49 | 0.021 | Oncogene | Carcinoembryonic antigen related cell adhesion molecule 6 |
CEACAM1 | 0.49 | 0.001 | Suppressor gene | Carcinoembryonic antigen related cell adhesion molecule 1 |
High level of PDGFRA expression in young CRC patients
Co-expression of PDGFRA with a CMS4 related factor
PDGFRA expression and PDGFRA-targeted drug response in PDC
PDC | Age | Sex | Cancer type | Stage | Cell type |
---|---|---|---|---|---|
#1 | 40 | M | Adenocarcinoma | IIIb | Poorly differentiated |
#2 | 28 | F | Adenocarcinoma | IIIb | Moderately differentiated |
#3 | 83 | F | Adenocarcinoma | IIIb | Moderately differentiated |
#4 | 80 | M | Adenocarcinoma | IIIb | Moderately differentiated |